|
Certolizumab (Cimzia) for early rheumatoid arthritis – first line |
NIHR HSRIC |
|
|
Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Certolizumab (Cimzia) for early rheumatoid arthritis – first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Certolizumab pegol is a Fab fragment humanised monoclonal antibody directed against tumour necrosis factor alpha (TNF-α) expressed in Escherichia coli and conjugated to polyethylene glycol (PEG). It is intended for the treatment of rheumatoid arthritis (RA) in combination with methotrexate (MTX).
The estimated prevalence of RA in England is 0.86%, equivalent to around 346,000 people. The annual incidence of RA is 1.5 per 10,000 in males and 3.6 per 10,000 in females, which equates to approximately 12,000 new diagnoses each year in the UK. In 2013-14, there were 52,319 admissions for RA in England, resulting in 19,044 bed days and 53,207 finished consultant episodes. In 2013, 730 deaths from RA were registered in England and Wales.
RA is currently incurable; however, symptoms can usually be managed. The goal of management is to suppress disease, control pain, reduce functional limitation, reduce risk of permanent joint damage and achieve clinical remission. The clinical management of RA includes physical therapy, surgical interventions and a range of pharmacological treatments including non-biological therapies (corticosteroids, MTX, sulfasalazine, leflunomide and azathioprine) and biological therapies (etanercept, abatacept, infliximab, adalimumab, golimumab, certolizumab pegol, and tocilizumab, all in combination with MTX). The biological therapies are currently only recommended for moderate to severe active RA after failure of at least two conventional non-biological therapies, including MTX. Certolizumab in combination with MTX is currently in phase III clinical trial study comparing its effect on sustained remission compared with placebo plus MTX. This trial is expected to complete in Sept 2015. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Certolizumab Pegol; Humans; Immunoglobulin Fab Fragments Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000366 Date abstract record published 04/03/2016 |
|
|
|